Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: A meta-analysis of 1324515 patients from observational studies

Diabetes, Obesity and Metabolism

Volumn 17, Issue 1, 2015, Pages 32-41

  Wang, T ^a,d   Wang, F ^b   Gou, Z ^c   Tang, H ^d   Li, C ^d   Shi, L ^a   Zhai, S ^d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Acute pancreatitis; Case control study; Cohort study; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Incretin based therapies; Meta analysis; Observational study

Indexed keywords

INCRETIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR;

ACUTE PANCREATITIS; ARTICLE; CONSENSUS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PUBLISHING; QUALITY CONTROL; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; PANCREATITIS; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; OBSERVATIONAL STUDIES AS TOPIC; PANCREATITIS; RECEPTORS, GLUCAGON; RISK FACTORS;

EID: 84919479662     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12386     Document Type: Article

References (49)

1. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs - FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Garber AJ, Abrahamson AJ, Barzilay JI et al. American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013; 19(Suppl. 1): 1-48.
4. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
5. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweight the potential risks. Diabetes Care 2013; 36: 2126-2132.
6. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis a case report. Diabetes Care 2006; 29: 471.
7. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1969-1970.
8. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available from URL: http://www.fda.gov/drugs/drugsafety/ucm343187.htm. Accessed 25 March 2014.
9. Knezvich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 2012; 69: 386-389.
10. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract 2011; 17: e48-e50.
11. Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013; 346: f3680.
12. Williams-Herman D, Round E, Swern AS et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14.
13. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119-145.
14. White WB, Cannon CP, Heller SR et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl Med 2013; 369: 1327-1335.
15. Scirica BM, Bhatt DI, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
16. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012; 98: 271-284.
17. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 48-56.
18. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014; 103: 269-275.
19. Li L, Shen J, Bala MM et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348: g2366.
20. Egger M, Schneider M, Smith GD. Spurious precision? Meta-analysis of observational studies. BMJ 1998; 316: 140-144.
21. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects - advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725-732.
22. Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract 2010; 88: S3-S9.
23. Dore DD, Seegar JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
24. Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-566.
25. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin A retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
26. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012; 14: 904-911.
27. Wenten M, Gaebler JA, Hussein M et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow up study. Diabet Med 2012; 29: 1412-1418.
28. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013; 346: f2267.
29. Seong J, Choi N, Kim J, Lee J, Kim Y, Park B. Dipeptidyl peptidase-4 inhibitor use and risk of acute pancreatitis in patients with type 2 diabetes. Drug Saf 2013; 36: 793-951.
30. Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014; 16: 273-275.
31. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014; 348: g2780.
32. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-539.
33. Giorda CB, Picariello R, Nada E et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014; 2: 111-115.
34. Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Saf 2014; 37: 521-528.
35. Loke YK, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from URL: www.cochrane-handbook.org. Accessed 25 March 2014.
36. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-2012.
37. Pearce N. Effect measures in prevalence studies. Environ Health Perspect 2004; 112: 1047-1050.
38. Wells GA, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Available from URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 25 March 2014
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
40. Littell J, Corcoran J, Pillai V. Systematic review and meta-analysis. New York: Oxford University Press, 2008.
41. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011. Available from URL: http://www.cochrane-handbook.org. Accessed 25 March 2014.
42. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 2002; 55: 893-899.
43. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
44. Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof 2008; 31: 370-389.
45. Sterne JA, Egger M, Moher D, et al. Chapter 10: Addressing reporting biases. In: Higgins J, Green S (eds), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011) The Cochrane Collaboration, 2011. Available from URL: http://www.cochrane-handbook.org. Accessed 25 March 2014.
46. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2006; 29: 1963-1972.
47. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
48. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes a retrospective cohort study. Diabetes Care 2009; 32: 834-838.
49. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32.